Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · IEX Real-Time Price · USD
2.000
+0.200 (11.11%)
At close: May 17, 2024, 4:00 PM
2.010
+0.010 (0.50%)
After-hours: May 17, 2024, 7:52 PM EDT
Company Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Martin A. Lehr |
Contact Details
Address: 2001 Market Street, Suite 3915 Unit #15 Philadelphia, Pennsylvania 19103 United States | |
| Phone | 267-225-7416 |
| Website | contexttherapeutics.com |
Stock Details
| Ticker Symbol | CNTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001842952 |
| CUSIP Number | 21077P108 |
| ISIN Number | US21077P1084 |
| Employer ID | 86-3738787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer and Director |
| Jennifer Minai-Azary | Chief Financial Officer and Treasurer |
| Alex C. Levit Esq. | Chief Legal Officer and Corporate Secretary |
| Christopher Beck M.B.A. | Senior Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | D | Notice of Exempt Offering of Securities |
| May 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |